Expression Of Macrophage Migration Inhibition Factor In Serum Of Patients With Prostate Cancer And Its Correlation With Prostate Specific Antigen

Objective To observe the expression of macrophage migration inhibition factor(MIF) in serum of patients with prostate cancer and its correlation with prostate specific antigen(PSA).Methods The levels of serum MIF were measured by an enzyme linked immunosorbent assay(ELISA)in patients with prostate cancer ,patients with benign prostatic hyperplasia(BPH) and healthy male adults as healthy controls.The serum PSA level was measured using a time resolved fluoroisnmunoassay (TRFIA). Results The positive rates of MIF in serum of prostate cancer,BPH and healthy controls were 100%(40/40),70%(14/20)and 85%(17/20)respectively.The MIF levels of patients with prostate cancer were significantly higher than those of the other two groups (P<0.0001), But there was no difference in serum levels between BPH and healthy controls (P>0.05). MIF expression was found to relate to the clinical stages and the degree of cell differentiation of prostate cancer (P<0.05), but not to bone metastasis (P>0.05). PSA was expressed more obviously in prostate cancer than in other two groups (P<0.0001), and The PSA levels of BPH were significantly higher than those of the healthy controls, But PSA expression was found to be not related to the clinical stages,the degree of cell differentiation and bone metastasis of prostate cancer (P>0.05).The MIF levels was not correlated with PSA in all serums (r2=0.111, P >0.05). Conclusions The levels of MIF were correlated significant -ly with the stage and grade of prostate cancer. MIF may play an important role in the oncogenesis and development of prostate cancer. It may be used as an candidate indicator for diagnosis,therapy and prognosis of prostate cancer. But it can not improve the sensitivity and specificity of PSA in detecting prostate cancer.